Verdict No. 3039 · Search date 2026-09-08 · Methodology v1.0
Oral curcumin or curcuminoid supplementation across mixed formulations,
does it really help with Reduction of LDL cholesterol in adults with dyslipidemia or metabolic disease?
30-Second Summary
D
Evidence Grade D · 30 · Safety caution
This verdict addresses LDL alone; HDL, triglycerides, and total cholesterol are separate outcomes.
Caution. Lipid-lowering medicines should not be stopped; gastrointestinal, bleeding, hepatic, and biliary precautions remain separate from efficacy.
What the
research showsGrade D with 30 points. The updated LDL estimate was null (SMD -0.17, 95% CI -0.43 to 0.09; P=.20), while earlier meta-analyses alternated between positive and null results.
research showsGrade D with 30 points. The updated LDL estimate was null (SMD -0.17, 95% CI -0.43 to 0.09; P=.20), while earlier meta-analyses alternated between positive and null results.
What the
ads claimThe evidence does not support statin replacement or myocardial-infarction prevention, and triglyceride results cannot substitute for LDL.
ads claimThe evidence does not support statin replacement or myocardial-infarction prevention, and triglyceride results cannot substitute for LDL.
Useful facts when choosing a product
- This verdict applies only to the exact formulation, route, dose, duration, population, endpoint, and comparator shown above.
- Conventional curcumin, turmeric powder, nano or micellar products, phospholipid phytosomes, piperine combinations, swallowed products, and topical oral products are not interchangeable.
- Caution. Lipid-lowering medicines should not be stopped; gastrointestinal, bleeding, hepatic, and biliary precautions remain separate from efficacy.
Chamgap Semantic Classification Code
Permanent code issued
S.curcumin.oral.ldl-cholesterol.reduce.placeboSupplements and nutraceuticals > Curcumin > Oral > LDL cholesterol > Reduction claim > Placebo or control care
The null latest synthesis remains retrievable under the claim intent; triglycerides and HDL are separate. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Curcumin |
| Source or part used | Curcumin/curcuminoids derived from Curcuma longa |
| Formulation or processing | Mixed conventional, nano, phytosomal and other oral forms |
| Route | Oral |
| Dose | Trial-specific |
| Duration | Weeks to months across trials |
| Population | Mixed adults with dyslipidemia, type 2 diabetes, or metabolic syndrome |
| Effect or condition | LDL-cholesterol reduction |
| Primary endpoint | Change in blood LDL cholesterol |
| Comparator | Placebo or control care |
| Duplicate-detection key | curcumin|mixed-oral-formulations|oral|adult-metabolic-disease|ldl-reduction|weeks-to-months |
Gap Measurement · Verdict 3039 · D 30
What the research actually shows
Meta-analyses from 2013-2025 with different population and formulation scopes were compared, centering the latest direct null result.
Why this is classified as D (30)
Conflicting syntheses and a null latest direct estimate yield D with 30 points.
Counterpoint. Some metabolic-disease analyses estimated roughly 6-10 mg/dL lower LDL, but this is not consistent with the broader updated analysis.
Rejudgment record. Independent Codex cross-check — One formulation, one route, one population, one claim, one principal endpoint and comparator
Scoring profile behind this grade
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R0 | Trials conflict in direction |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (D).
Cross-check — AI research and Codex final gate
AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Curcumin and blood lipid levels: an updated systematic review and meta-analysis of randomised clinical trials | The cited design and its allocation, masking, endpoint, and analysis limitations were independently checked. | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint is preserved; secondary and mechanistic outcomes remain separate. | The verified numerical result is preserved in the English reader answer and rationale; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and verified analysis limitations. | |
| The effect of curcumin on lipid profile and glycemic status of patients with type 2 diabetes mellitus: a systematic review and meta-analysis | The cited design and its allocation, masking, endpoint, and analysis limitations were independently checked. | 2 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint is preserved; secondary and mechanistic outcomes remain separate. | The verified numerical result is preserved in the English reader answer and rationale; missing confidence intervals were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and verified analysis limitations. |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-09-08).
Saeedi F et al. Arch Physiol Biochem. 2022;128:1493-1502. PMID: 36264280. DOI: 10.1080/13813455.2020.1779309.
checkedYuan F et al. Diabetes Res Clin Pract. 2022;183:109119. PMID: 35754684. DOI: 10.1016/j.diabres.2021.109119.
checkedResearch and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Curcumin for LDL Cholesterol—An Updated Meta-Analysis Did Not Confirm a Reduction — Evidence Grade D·30. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/oral-curcumin-metabolic-disease-ldl-cholesterol/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.